We are live on ! Find out more
CYTH

Cyclo Therapeutics, Inc. Common Stock
CYTH

Delisted

CYTH was delisted on the 25th of March, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Cyclo Therapeutics, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 22 → 0 (-22)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $1.33M → $0 (-$1.33M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 21

Holders
–
Holders Change
-22
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$353K
2
FFVM
Founders Fund V Management
California
-$284K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$89.9K
4
FFVM
Founders Fund VI Management
California
-$64.9K
5
BlackRock
BlackRock
New York
-$49.5K

CYTH Hedge Fund Activity: Q1 2025 in Review

0 of the 7,470 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q1 2025, worth a combined $0 — down 100% from $1.33M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CYTH and 0 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $353K sold.

  • 0 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q1 2025, down from 22 in Q4 2024.
  • Funds reported $0 of Cyclo Therapeutics, Inc. Common Stock stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q1 2025 and 21 closed out, a net change of -21 holders.
  • The largest Cyclo Therapeutics, Inc. Common Stock seller in Q1 2025 was Vanguard Group, an estimated $353K sold.

Based on aggregated 13F filings for Q1 2025.